Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
| Revenue (Most Recent Fiscal Year) | $9.77M |
| Net Income (Most Recent Fiscal Year) | $-109.00M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.77 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -2728.04% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -56.19% |
| Return on Assets (Trailing 12 Months) | -41.84% |
| Current Ratio (Most Recent Fiscal Quarter) | 17.76 |
| Quick Ratio (Most Recent Fiscal Quarter) | 17.76 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.13 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.90 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.13 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.34 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.42 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 325.83M |
| Free Float | 314.50M |
| Market Capitalization | $1.22B |
| Average Volume (Last 20 Days) | 4.78M |
| Beta (Past 60 Months) | 1.19 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 3.48% |
| Percentage Held By Institutions (Latest 13F Reports) | 77.70% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |